These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 20493444

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
    Lingnau A, Miller K, Steiner U, Jentzmik F, Weikert S, Schostak M.
    Aktuelle Urol; 2009 Sep; 40(5):307-9. PubMed ID: 19637135
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intravesical mitomycin C for superficial transitional cell carcinoma.
    Bolenz C, Cao Y, Arancibia MF, Trojan L, Alken P, Michel MS.
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1273-82. PubMed ID: 16925493
    [Abstract] [Full Text] [Related]

  • 7. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
    Gudjónsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, Richthoff J, Hagberg G, Grabe M, Bendahl PO, Månsson W, Liedberg F.
    Eur Urol; 2009 Apr; 55(4):773-80. PubMed ID: 19153001
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS, Chow NH, Lin JS, Yang WH, Tong YC.
    Anticancer Res; 1998 Apr; 18(6B):4717-21. PubMed ID: 9891547
    [Abstract] [Full Text] [Related]

  • 13. Intravesical chemotherapy for superficial bladder tumors category Ta/T1: who should be treated and how?
    Kurth KH.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):30-5. PubMed ID: 8727808
    [Abstract] [Full Text] [Related]

  • 14. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?
    Oddens JR, van der Meijden AP, Sylvester R.
    Eur Urol; 2004 Sep; 46(3):336-8. PubMed ID: 15306104
    [Abstract] [Full Text] [Related]

  • 15. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H.
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.